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Figure 6
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Figure 12

Biotinylated-NEP binds to streptavidinconjugated biotinylated-red blood cells.
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AMYLOID PEPTIDE INACTIVATING
ENZYME TO TREAT ALZHEIMER'S
DISEASE PERIPHERALLY

can reduce the number of preformed amyloid plaques (Marr,
R. A. eta!. (2003) Neprilysin gene transfer reduces amyloid
pathology in mouse models ofAlzheimer's disease. J. Neurosci. 23:1992-1996). This is the first report that shows that
neprilysin can actually be used to "dissolve" preformed
plaques. Since neprilysin does not degrade aggregated A~,
this demonstrates that the aggregated A~ must be in a
dynamic equilibrium with free A~ or small A~ oligomers. We
have also conducted preliminary experiments designed to test
the effect of neprilysin expression in the brain of an hAPP
mouse model as a way to degrade A~ and prevent amyloid
deposits from forming. As shown in FIG. 3, we found that
using the lentivirus-neprilysin construct to express neprilysin
in the hippocampus of the 120 human hAPP transgenic mouse
model of AD, virtually eliminated amyloid deposits in the
9-month old mouse. (Id.). In the lentivirus-NEP treated brain
(FIG. 3B, right) there is a small amount of diffuse light
staining material, indicative of amyloid peptide, as compared
to the controllentivirus-GFP (FIG. 3A, right). (Id.).
More recently interest has emerged in targeting the clearance of A~ peptides as a therapeutic approach, primarily
through the use of antibodies to A~. This approach involves
either immunizing with A~ (Schenk D, eta!. (1999) Immunization with amyloid-~ attenuates Alzheimer-disease-like
pathology in the PDAPP mouse. Nature 400:173-177; Janus
C, et a!. (2000) A peptide immunization reduces behavioral
impairment and plaques in a model ofAlzheimer's disease.
Nature 408:979-982; Morgan D et a!. (2000) A~ peptide
vaccination prevents memory loss in an animal model of
Alzheimer's disease. Nature 408:982-985; Weiner H L, eta!.
(2000) Nasal administration of amyloid-~ peptide decreases
cerebral amyloid burden in a mouse model of Alzheimer's
disease.AnnNeurol48:567-579; Das P, eta!. (2001)Reduced
effectiveness ofA~ 1-42 immunization inAPP transgenic mice
with significant amyloid deposition. Neurobiol Aging
22:721-727) or through the passive administration ofA~ antibodies (Bard F, et a!. (2000) Peripherally administered antibodies against amyloid ~-peptide enter the central nervous
system and reduce pathology in a mouse model ofAlzheimer
disease. Nat Med 6:916-919; DeMattos R B, eta!. (2001)
Peripheral anti-A~ antibody alters CNS and plasma A~ clearance and decreases brain A~ burden in a mouse model of
Alzheimer's disease. Proc NatlAcad Sci USA 98:8850-8855;
DeMattos R B, eta!. (2002)Brain to plasma amyloid-~ efflux:
a measure of brain amyloid burden in a mouse model of
Alzheimer's disease. Science 295:2264-2267). The promising results derived from A~ immunization studies in mice led
to clinical trials using A~ immunization that initially
appeared to produce beneficial results (Hock C, eta!. (2003)
Antibodies against beta-amyloid slow cognitive decline in
Alzheimer's disease. Neuron. 38:547-54). However, several
patients developed encephalitis (Greenberg S M, eta!. (2003)
Alzheimer disease's double-edged vaccine. Nat Med. 9:389390) and the clinical trails were stopped. Consequently there
exists a need to safely and effectively treat Alzheimer's disease.
One of the theories that immerged from the immunological
studies was that passive immunization with A~ antibodies
resulted in an efflux of A~ from the brain into the plasma
producing a peripheral "sink effect", DeMattos eta!., 2001,
2002. It has been shown that peripheral administration of an
anti-A~ monoclonal antibody resulted in a rapid 1,000 fold
increase in plasma A~ and a marked reduction in A~ deposition in the brain, DeMattos eta!., 2001. Subsequently, it was
shown that introduction of two A~-binding compounds, ganglioside GM1 and gelsolin, to bind plasma A~ in hAPP transgenic mice, resulted in a lowering of brain A~ levels by 50%
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This application is a national phase of PCT/US2005/
030396 which claims priority from U.S. Provisional Application No. 60/604,700 filed Aug. 27, 2004, the disclosures of
which Applications are incorporated by reference herein. The
benefit of the filing and priority dates of the International and
U.S. Applications is respectfully requested.
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GOVERNMENT INTEREST IN THE INVENTION
15

This invention was made with Government support under
four grants: (1) grant no. UKRF#465181 awarded by the
Alzheimer's Association, (2) grant no. DA02243 awarded by
the National Institute on Drug Abuse, (3) grant no. AG19323
awarded by the National Institute on Aging, and (4) grant no.
AG024899 also awarded by the National Institute on Aging.
The Government has certain rights in this invention.

20

FIELD OF THE INVENTION
25

The present invention relates to methods of and transduced
stem cells and modified peptidase for preventing amyloid
peptide (A~) accumulation, and plaque formation in the brain
by raising amyloid peptide inactivating enzyme activity in the
periphery. The present invention also relates to methods of
lowering plasma A~ levels as a way to lower brain A~ using
expression of amyloid peptide inactivating enzymes, like
neprilysin, on hematopoietic cells. The present invention also
relates to a method of treating and/ or preventing Alzheimer's
disease.

30
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BACKGROUND OF THE INVENTION
The incidence of Alzheimer's disease (AD) is estimated to
currently affect up to 4 million Americans and this number
will certainly increase as our population continues to age.
Approximately 3% of the population between ages 65 to 74
suffer from AD, and this value increases with increasing age.
Since AD patients generally live 8 to 10 years after the disease
is diagnosed, the financial burden AD imposes on our
economy is estimated to exceed $100 billion and will continue to increase. Although there are a number of acetylcholinesterase inhibitors as approved drugs that can improve the
symptoms of AD patients over the short term, no current
therapy can retard disease progression. It is widely accepted
that the oligomerization and subsequent deposition of amyloid~ peptides (A~) is a major factor in AD. Thus considerable effort has been expended in the development of drugs
that can selectively inhibit the ~ andy secretases responsible
for A~ formation. To date no such drugs have reached the
marketplace.
In recent years attention has been given to the peptidases
that are involved in amyloid peptide (e.g., A~) clearance, such
as neprilysin and insulysin. It has been shown that inhibition
or deletion of these peptidases in rodent models leads to
elevated A~, and that introduction of these peptidases into the
brain of transgenic mice expressing human amyloid precursor protein (hAPP) can lead to a reduction inA~ levels (Leissring M A, et a!. (2003). Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation,
secondary pathology, and a premature death. Neuron 40,
1087-1 093). In addition expression of neprilysin in the brain
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or more (Matsuoka Y, et a!. (2003) Novel therapeutic
approach for the treatment ofAlzheimer's disease by peripheral administration ofagents with an affinity to beta-amyloid.
J Neurosci, 23:29-33). In this study it was demonstrated that
the lowering of brain A~ by ganglioside GMl was not due to
ganglioside GMl crossing the blood-brain barrier. It has also
been shown that exogenous A~ is rapidly transported from the
CSF to plasma, exhibiting a half-time of -30 min (GhersiEgea J F, eta!. (1996) Fate ofcerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem.
67:880-883; Shibata M, et a!. (2000) Clearance of Alzheimer's amyloid-ss(l-40) peptide from brain by LDL receptorrelated protein-] at the blood-brain barrier. J Clin Invest.
106: 1489-99). Yet another example is to use a soluble receptor for advanced glycation end products (RAGE) in the blood
to bind A~ (DeaneR. eta!. (2003)RAGE mediates amyloid-~
peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913).
The present invention comprises methods of lowering
plasma A~ levels as a way to lower brain A~ using peripheral
expression of amyloid peptide inactivating enzymes, like
neprilysin, on hematopoietic cells. The methods a flowering
plasma A~ comprise i) peripheral expression of an amyloid
peptide inactivating enzyme in hematopoietic stem cells comprising a viral vector to infect bone marrow stem cells with a
neprilysin-expressing or other A~-degrading peptidase-expressing construct; ii) coupling of neprilysin or other A~
degrading peptidases to hematopoietic cells; iii) modifying
amyloid peptide inactivating enzymes such that the enzyme
will bind to hematopoietic cells; or iv) use of liposomes or
other agents to introduce neprilysin or other A~ degrading
peptidases into hematopoietic cells.

4

In another preferred embodiment, there is a method of
reducing amy laid peptide in the brain comprising inactivating
peripheral amyloid peptide by peripheral expression of amyloid peptide inactivating enzyme comprising the steps of:
a. generating a recombinant viral or plasmid vector comprising a nucleotide sequence encoding an amyloid peptide
inactivating enzyme operatively linked to a promoter; and
b. introducing the vector into hematopoietic stem cells in
vivo by injection, such that the amyloid peptide inactivating
10
enzyme is expressed on the surface of or secreted from
hematopoietic cells,
In another aspect of the present invention, there are transduced stem cells for treating and/or preventing Alzheimer's
disease. In a preferred embodiment stem cells are transduced
15
with a vector encoding an amyloid peptide inactivating
enzyme. Preferably the stem cells are hematopoietic stem
cells. In a preferred embodiment the vector is a viral vector,
and most preferably a lentivirus or adena associated viralvec20 tor. In a preferred embodiment the amyloid peptide inactivating enzyme is a peptidase, and most preferably, the peptidase
is neprilysin or a biologically active derivative or fragment
thereof.
In another aspect of the invention, there is a method of
25 reducing amy laid peptide in the brain comprising inactivating
peripheral amyloid peptide by coupling amyloid peptide
inactivating enzymes to hematopoietic cells. In a preferred
embodiment, method comprises the steps of:
a. taking a sample of hematopoietic cells from a patient;
b. coupling one or more hematopoietic cells to one or more
30
amyloid peptide inactivating enzyme ex vivo; and
c. introducing the amyloid peptide inactivating enzymebound-hematopoietic cells into the blood of the patient;
Coupling may be performed by one of several methods.
35 Preferably, the coupling is facilitated by biotinylation of the
enzyme and the hematopoietic cells using streptavidin and/or
SUMMARY OF THE INVENTION
avidin to couple biotin-bound molecules together. In another
preferred method coupling is facilitated by chemical crossThe present invention addresses the need for a method of
preventing and treating Alzheimer's disease by inactivating
linking reagents such as glutaraldehyde.
40
In another preferred embodiment the coupling is effected
peripheral amyloid peptide.
by modifying one or more enzyme so that it binds to one or
In one aspect of the present invention, there is a method for
more hematopoietic cell. Modification preferably includes
the reducing amyloid peptide in the brain of a mammalian
host comprising inactivating peripheral amyloid peptide by
coupling a C-terminal human red blood cell binding peptide
peripherally expressing an effective amount of an amyloid
sequence to amyloid peptide inactivating enzyme such that
peptide inactivating enzyme to reduce, via efflux, amyloid 45 the C-terminal human RBC binding peptide sequence-bound
enzyme couples with one or more hematopoietic cells. Modipeptide from the brain. Peptidase is a preferred amyloid pepfication also preferably includes coupling an antibody to
tide inactivating enzyme used in the aspects and embodiments of this invention. The peptidase may be introduced by
hematopoietic cells to an amyloid peptide inactivating
ex vivo or in vivo techniques known by one of ordinary skill
enzyme such that the antibody-bound enzyme couples with
in the art.
so one or more hematopoietic cells. Modification also preferIn a preferred embodiment, the invention provides a
ably includes coupling the C-terminal red blood cell binding
method for reducing amyloid peptide in the brain comprising
peptide sequence to the enzyme, or coupling an antibody to
inactivating peripheral amyloid peptide by peripheral expreshematopoietic cells to the enzyme. Modification also preferably includes adding an anchor, such as glycoinositol phossion of amyloid peptide inactivating enzymes comprising the
55 pholipid (GPI), to an amyloid inactivating enzyme to permit
steps of:
a. generating a recombinant viral or plasmid vector cominsertion of the amyloid peptide inactivating enzyme into the
prising a nucleotide sequence encoding an amyloid peptide
membrane of a hematopoietic cell.
In another preferred aspect of the present invention, there is
inactivating enzyme;
b. taking a sample of hematopoietic stem cells from a
a method of reducing amyloid peptide in the brain comprising
60 modifYing in vitro one ore more amyloid peptide inactivating
patient;
c. introducing ex vivo the recombinant viral or plasmid
enzyme such that the modified amyloid peptide inactivating
vector into one or more hematopoietic stem cells of the
enzymes binds to one or more hematopoietic cells and introsample; and
ducing the one or more modified amy laid peptide inactivating
enzyme coupled hematopoietic cells into the blood of a
d. transplanting the hematopoietic stem cells of step c. into
the patient, such that the amyloid peptide inactivating enzyme 65 patient. Modification of the amyloid peptide inactivating
enzyme comprise the methods disclosed herein and others
is expressed on the surface of hematopoietic cells or secreted
from hematopoietic cells,
that are known or become known to one skilled in the art of
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coupling molecules, preferably, coupling amyloid peptide
inactivating enzymes to hematopoietic cells.
In still another aspect of the invention, there is a method of
reducing amyloid peptide in the brain comprising inactivating
peripheral amyloid peptide by introducing an amyloid peptide inactivating enzyme into hematopoietic cells of a patient
via liposomes or other delivery reagents. The amyloid peptide
inactivating enzyme-containing liposome may be delivered
ex-vivo into the hematopoietic cells of a patient and then
transplanted into a patient or delivered in vivo into the
hematopoietic cells of a patient.
It is yet another aspect of the invention to provide methods
for preventing and/or treating a patient with Alzheimer's disease utilizing the methods described herein to reduce levels or
prevent accumulation of amyloid peptide in the brain. In one
preferred embodiment, the method comprises administering
(ex vivo or in vivo) to the hematopoietic stem cells of a patient
in need thereof a therapeutically effective amount of a recombinant viral vector or plasmid vector comprising a nucleotide
sequence encoding an amyloid peptide inactivating enzyme
operatively linked to a promoter such that it is expressed on
the surface of or secreted from hematopoietic cells. In another
preferred embodiment, a therapeutically effective amount of
stem cells transduced with a DNA vector encoding an amylaid peptide inactivation enzyme are administered to a
patient. In another preferred embodiment, the method comprises administering to a patient in need thereof a therapeutically effective amount of an amyloid peptide inactivating
enzyme to peripheral hematopoietic cells by the methods
described herein to inactivate peripheral amyloid peptide
resulting in a reduction, via efflux, of amyloid peptide from
the brain.
These and other aspects of the invention will be more fully
understood from the following description of the invention
and the referenced drawings attached hereto.

0.1% cells appearing as CD45.1 +cells. This illustrates that
bone marrow cells can be transplanted from a donor to a
recipient.
FIGS. 5 (A and B) illustrates the flow cytometric analysis
of hematopoietic bone marrow cells from a bone marrow
transplant recipient mouse for neprilysin expression (NEP)
and inactive neprilyisn (NEPx) compared to an untreated
mouse.
FIG. SA shows the ability to transplant NEP-lentivirus
transduced bone marrow cells from a donor to a recipient
mouse: Left-a histogram of lentivirus-NEP-transduced
bone marrow stem cells from a donor mouse transplanted to a
recipient mouse; Center-a histogram of a recipient mouse
without bone marrow transplantation; and Right-a histogram of a recipient mouse after bone marrow transplantation
without treatment with FITC conjugated anti-NEP antibody.
FIG. 5 B shows data in a repeat of the experiment. The
NEP-lentivirus was used to transduce bone marrow stem cells
from a donor mouse, which were transplanted into a twomonth old recipient mouse to produce neprilysin expression
on white blood cells. About 65% of the bone marrow cells
used for transplantation expressed neprilysin. Cells in the M1
region are neprilysin positive cells. Control is a histogram of
a recipient mouse without bone marrow transplantation.
There are less than 2% cells appearing as neprilysin positive
cells. The panel labeled NEP is a histogram of cells from a
recipient mouse receiving NEP-lentivirus transduced bone
marrow cells and shows greater than 20% of the white blood
cells express neprilysin. The panel labeled NEPx is a histogram of cells from a recipient mouse receiving inactive NEPlentivirus transduced bone marrow cells and shows greater
than 20% of the white blood cells express inactive neprilysin
FIG. 6 shows reduced A~ in the brain from NEP peripherally expressed on white blood cells.
FIG. 7 shows reduced amyloid deposits in the brain of an
hAPP transgenic mouse in the brain from NEP peripherally
expressed on white blood cells.
FIG. 8 (A-B) illustrates lentiviral virus constructs for
expression of neprilysin on red blood cells. Similar constructs
can be used for expressing other A~ degrading enzymes.
FIG. 9 shows the time course of NEP biotinylation with
biotin-N -hydroxysuccinimide
FIG. 10 shows that biotinylated NEP (as shown in FIG. 9)
retains enzymatic activity.
FIG. 11 shows that red blood cells can be biotinylated.
FIG. 12 shows that biotinylated NEP can be linked to
biotinylated red blood cells through streptavidin.
FIG. 13 shows a modified form of neprilysin in which a
C-terminal human red blood cell binding peptide sequence is
attached. SS represents a secretion signal.
FIG. 14 shows that modified neprilysin containing a C-terminal human red blood cell binding peptide sequence is
bound to red blood cells.
FIG. 15 shows a modified form of neprilysin in which a
C-terminal single chain antibody directed against a red blood
cell surface epitope sequence is attached.
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates a lentiviral virus construct used for
expression of neprilysin on hematopoietic cells. Similar constructs can be used for expressing other A~ degrading
enzymes.
FIG. 2 illustrates that the expression of neprilysin (NEP) in
A~ secreting CHO cells (7PA2) efficiently reduces A~ in the
media. NEPx is an inactive point mutant of neprilysin on the
cell surface. SecNEP is an engineered secreted form of neprilysin. NEP is wild type neprilysin on the cell surface.
FIG. 3 illustrates A~ deposits in the 9-month control (lentivirus-GFP) (FIG. 3A, left) or lentivirus-NEP transduced
(FIG. 3B, right) 120 hAPP transgenic mouse. The arrows
indicate A~ deposits, which are numerous and dense in the
control virus treated mouse. In the lentivirus-NEP treated
brain there is a small amount of diffuse light staining material.
FIG. 4 (A-C) illustrates the flow cytometric analysis of a
bone marrow transplanted recipient mouse (CD45.2+) for
expression of donor-specific lenkocyte common antigen variant CD45 .1. Panel A is a histogram of a recipient mouse's
white blood cells 30 days after bone marrow transplantation.
FITC conjugated anti CD45.1 antibody A20 (PharMingen)
was used. Cells in the M1 region are CD45 .1 +donor cells and
represent about 30% of the total cells. Panel B is a histogram
of the same recipient mouse's white blood cells as in the left
panel, but without FITC conjugated anti CD45.1 antibody.
There are less than 0.1% cells appearing as CD45.1 positive
cells, while panel C is a histogram of a recipient mouse
without bone marrow transplantation. There are less than
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DETAILED DESCRIPTION
All patents, patent applications and literature cited in this
description are incorporated in their entirety by reference
herein. In the case of inconsistencies, the present disclosure,
including definitions, will prevail.
As used herein, an "amyloid peptide" includes beta or
gamma amyloid peptides (i.e.,A~ andAy, respectively). Pref-
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erably, the peptide is amyloid beta peptide. More preferably,
the beta peptide isA~ 1 _40 or A~ 1 _ 42 . Most preferably, the beta
peptide is A~ 1 _ 42 .
As used herein, an "amyloid peptide inactivating enzyme"
encompasses a group of functionally or structurally related
proteins that modulate, bind to, and/or hydrolyze amyloid
peptides, and prevent the peptides from depositing as plaques
or fibrils. Preferably, toxic side-effects are minimized. By
"inactivating" it is meant that the enzyme may functionally
prevent amyloid peptides from aggregating and from forming
plaques. Preferably, "inactivating" refers to degrading, clearing and/or dissolution of the amyloid peptide, plaque or fibril.
Preferably "degrading" or "clearing" refers to the act of
changing a protein, like A~, or a protein complex, like amylaid plaques and fibrils, to a less complex protein or protein
complex, respectively. Degradation of A~ is preferably by
hydrolysis, a chemical process whereby a compound is
cleaved into two or more simpler compounds with the uptake
of the Hand OH parts of a water molecule on either side of the
chemical bond cleaved (e.g., insulysin as shown in U.S. Published Patent Application No. 2003/0165481). Degradation
of A~ plaques may be caused by an equilibrium between
fibrillary A~ and monomeric, dimeric or trimeric A~, the
monomeric, dimeric and trimeric forms ofA~ are hydrolyzed
by neprilysin (Kanemitsu H, Tomiyama T, Mori H. (2003)
Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological
oligomeric form. Neurosci Left. 350: 113-116) thus "pulling"
theA~ out of the plaque through equilibration with the monomer or low molecular oligomers and leading to a dissolution
of the plaque. Preferably, the enzyme is a peptidase. Nonlimiting examples of the enzyme include insulysin (also
known as insulin degrading enzyme or IDE), neprilysin (also
known to as endopeptidase 24.11, NEP, or CALLA), neprilysin 2 (also known as secreted endopeptidase, secNEP, or
membrane metallo-endopeptidase-like 2), endopeptidase
24.15 (also known as thimet oligopeptidase 1), endopeptidase
24.16 (also known as neurolysin), endothelin converting
enzyme, angiotensin converting enzyme (also known as
dipeptidase A), plasmin, MMP-9 (also known as gelatinase
B), or similar peptidases or a combination thereof.
As used herein, the terms "bind" or "link," or "binds" or
"links", or "binding" or "linking" means any interaction
between two or more molecules by covalent or noncovalent
forces, Van der waals forces, electrostatic forces, and/or
hydrostatic forces.
As used herein, the term "biologically active" in reference
to a nucleic acid, protein, protein fragment or derivative
thereof is defined as an ability of the nucleic acid or amino
acid sequence to mimic a known biological function elicited
by the wild type form of the nucleic acid or protein.
As used herein, the terms "coupling" or "coupled" or
"couple" means any interaction, association with, attachment, conjugation, linking, or binding of one molecule (ineluding compounds, labels and ligands, amino acid sequence,
or nucleic acid sequence) to another molecule, by direct or
indirect means, using reactive groups, either in the molecules
per se or in a chemical or molecule added for that purpose, in
such a way as to allow each of the molecules to function in
their intended manners.
As used herein, the term "expression" means the detectable
effect of a gene, like a nucleic acid sequence encoding a
peptidase or biologically active derivative or fragment. The
term "express" means to manifest the detectable effect of a
gene. A gene may be expressed inside a cell, on the surface of
a cell or be secreted by the cell.

As used herein, the terms "hematopoietic" and "hemopoietic" are used interchangeably and mean pertaining to or
relating to the formation of blood cells.
As used herein, the terms "hematopoietic cells" and
"hemopoietic cells" are used interchangeably herein and refer
to any cell pertaining to or relating to the blood, including
white blood cells (WBCs) that fight infection and inflammations (e.g., leukocytes, lymphocytes), red blood cells (RBCs)
that carry oxygen (e.g., erythrocytes), and platelets that are
responsible for blood clotting.
As used herein, "hematopoietic stem cell(s)", "hemopoietic stem cells", "hematopoietic progenitor cell(s)" and
"hemopoietic progenitor cell(s)" are used interchangeably
herein and refer to any precursor cell whose daughter cells
may differentiate into various cells that are found in mammalian blood systems, including, white blood cells that fight
infection and inflammations (e.g., leukocytes, lymphocytes),
red blood cells that carry oxygen (e.g., erythrocytes), and
platelets that are responsible for blood clotting.
As used herein, the term "inactivate" refers to the act of
degrading, clearing and/or dissolving A~ from the periphery
or the central nervous system.
As used herein, the term "maintenance", when used in the
context of delivery to hematopoietic stem cells, denotes the
ability of introduced DNA to remain present in the cell. When
used in other contexts, it means the ability of targeted DNA to
remain present in the targeted cell or tissue so as to impart a
therapeutic effect.
As used herein, the term "mammalian host" includes members of the animal kingdom including but not limited to
human beings.
As used herein, the term "operatively linked" refers to the
linkage of a DNA segment to another DNA segment in such
a way as to allow the segments to function in their intended
manners. A DNA sequence encoding a gene product is operatively linked to a regulatory sequence when it is ligated to the
regulatory sequence, such as, for example, promoters,
enhancers and/or silencers, in a manner which allows modulation of transcription of the DNA sequence, directly or indirectly. For example, a DNA sequence is operatively linked to
a promoter when it is ligated to the promoter downstream
with respect to the transcription initiation site of the promoter,
in the correct reading frame with respect to the transcription
initiation site, and allows transcription elongation to proceed
through the DNA sequence. An enhancer or silencer is operatively linked to a DNA sequence coding for a gene product
when it is ligated to the DNA sequence in such a manner as to
increase or decrease, respectively, the transcription of the
DNA sequence. Enhancers and silencers may be located
upstream, downstream or embedded within the coding
regions of the DNA sequence. A DNA for a signal sequence is
operatively linked to DNA coding for a polypeptide if the
signal sequence is expressed as a preprotein that participates
in the secretion of the polypeptide. Linkage of DNA
sequences to regulatory sequences is typically accomplished
by ligation at suitable restriction sites or via adapters or linkers inserted in the sequence using restriction endonucleases
known to one of skill in the art.
As used herein, the term "patient" includes members of the
animal kingdom including but not limited to human beings.
As used herein, the term "peripheral" or "periphery" means
relating to the outside of, or being situated outside of, the
central nervous system.
As used herein, a "promoter" can be any nucleotide
sequence that is active, and controls transcription in a eukaryotic cell. The promoter may be active in either or both eukaryotic and prokaryotic cells. Preferably, the promoter is active
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in mammalian cells. Most preferably, the promoter is active in
mammalian hematopoietic cells. The promoter may be constitutively expressed or inducible.
As used herein, a "selectable marker" includes a gene
product that is expressed by a cell that stably maintains the
introduced DNA, and causes the cell to express an altered
phenotype such as morphological transformation, or an enzymatic activity. Isolation of cells that express a transfected
gene is achieved by introduction into the same cells a second
gene that encodes a selectable marker, such as one having an
enzymatic activity that confers resistance to an antibiotic or
other drug. Examples of selectable markers include, but are
not limited to, thymidine kinase, dihydrofolate reductase,
aminoglycoside phosphotransferase, which confers resistance to amino glycoside antibiotics such as kanamycin, neomycin and geneticin, hygromycin B phosphotransferase, xanthine-guanine phosphoribosyl transferase, CAD (a single
protein that possesses the first three enzymatic activities of de
novo uridine biosynthesis--carbamyl phosphate synthetase,
aspartate transcarbamylase and dihydroorotase ), adenosine
deaminase, and asparagine synthetase (Sambrook et a!.
Molecular Cloning, Third Edition Chapter 16. 2001), incorporated in its entirety by reference herein.
As used herein, the terms "stem cell(s)" and "progenitor
cell( s)"are used interchangeably and mean any precursor cell
whose daughter cells may differentiate into other cell types.
As used herein, the term "therapeutically effective
amount" means an amount sufficient to inactivate amyloid
peptide in the periphery and/or the central nervous system.
In one aspect the present invention discloses ex vivo and in
vivo techniques for delivery and expression of a DNA
sequence of interest to the periphery of a mammalian host.
One of the ex vivo techniques involves culture of cells, in vitro
transfection of the DNA sequence, DNA vector or other delivery vehicle of interest into the cells, followed by transplantation of the modified cells to the target joint of the mammalian
host, so as to effect in vivo expression of the gene product of
interest.
It will be understood by the artisan of ordinary skill that the
preferred source of cells for treating a human patient is the
patient's own tissues, such as autologous bone marrow, and
preferably autologous hematopoietic stem cells. Hematopoietic stem cells may differentiate to white cells (e.g., leukocytes), red cells (e.g., erythrocytes) and platelets.
In one embodiment, the present invention provides a
method of employing as the DNA sequence a gene capable of
encoding an amyloid peptide inactivating enzyme or a biologically active derivative or fragment thereof, and employing as a vector any DNA vector known to one of ordinary skill
in the art capable of stable maintenance within the targeted
cell or tissue upon delivery, regardless of the method of delivery utilized. The method of this invention provides introducing at least one gene encoding an amyloid peptide inactivating enzyme into at least one cell of a target tissue for treating
the mammalian host. Preferably the target tissue is bone marrow, and preferably the target cell is a hematopoietic stem
cell, however, any progenitor cell may be targeted for delivery
into liver, lung, kidney, muscle or other tissues in contact with
blood. The method of this invention further provides transplantation of infected target cells into a mammalian host for
expression of the amyloid peptide inactivating enzyme on cell
surfaces. Preferably the amyloid peptide inactivating enzyme
is expressed on the surface of, or secreted by, blood cells such
as, platelets, red blood cells and white blood cells, or a combination of any of the foregoing. Most preferably, the amyloid
peptide inactivating enzyme is expressed on red blood cells
(e.g., erythoroids, erythrocytes).

The amyloid peptide inactivating enzyme of the present
invention is preferably a peptidase or a biologically active
derivative or fragment thereof. The peptidase, including some
biologically active variants thereof may be insulysin (also
known as insulin degrading enzyme or IDE) [human IDE
GenebankAccession # NM004969]; neprilysin (also known
to as endopeptidase 24.11, NEP, or CALLA) [human NEP
Genebank Accession #s NM000902, NM007287,
NM007289, NM007288]; neprilysin 2 (also known as
secreted endopeptidase, secNEP, or membrane metallo-endopeptidase-like 2) [human NEP2 Genebank Accession #
NM033467]; endopeptidase 24.15 (also known as thimet oligopeptidase 1) [human endopeptidase 24.15 Genebank
Accession# NM003249]; endopeptidase 24.16 (also known
as neurolysin) [human endopeptidase 24.16 Genebank
Accession# NM020726]; endothelin converting enzyme [human endothelin converting enzyme 1 GenebankAccession #
NM001397; human endothelin converting enzyme 2
Genebank Accession# NM014693]; angiotensin converting
enzyme (also known as dipeptidase A) [human angiotensin
converting enzyme Genebank Accession #s NM 000789,
NM152831, NM152830]; plasmin [human plasmin derived
from human plasminogen Genebank Accession #000301];
MMP-9 (also known as gelatinase B) [human MMP-9
Genebank Accession# NM 004994], or similar peptidases.
Preferably, the peptidase is neprilysin.
This invention also includes other biologically active
derivatives or fragments (i.e., variants) ofpeptidases that are
substantially identical polynucleotides that hybridize to the
complement of a nucleic acid sequence encoding a peptidase
under stringent hybridization conditions for the isolation of
nucleic acids that encode peptidases that modulate and/or
bind to an amyloid peptide, thereby inactivating the amyloid
peptide. Highly stringent conditions involve hybridizing at
68° C. in 5xSSC/5xDenhart's solution/1.0% SDS, and washing in 0.2xSSC/0.1% SDS at room temperature. Moderately
stringent conditions include washing in 3xSSC at 42° C. The
parameters of salt concentration and temperature can be varied to achieve optimal level of identity between the primer
and the target nucleic acid. Additional guidance regarding
such conditions is readily available in the art, for example,
Sambrook and Russel, Molecular Cloning, a laboratory
manual, (3rd ed.), Cold Spring Harbor Laboratory Press, New
York, (2001) and F. M. Ausubel eta! eds., Current Protocols
in Molecular Biology, John Wiley and Sons (1994).
The direct delivery of the DNA vector molecule to the
target cell or tissue may be a viral or plasmid DNA vector
molecule. This method includes employing the biologic
means of utilizing a virus to deliver the DNA vector molecule
to the target tissue. Preferably the virus is a pseudovirus, the
genome having been altered such that the pseudovirus is
capable only of delivery and stable maintenance within the
target cell, but not retaining an ability to replicate within the
target cell or tissue. Most preferably, the virus is attenuated,
the strain having been selected for diminished virulence so as
to not spread disease.
The viral genome may be further manipulated by recombinant DNA techniques such that the viral genome acts as a
DNA vector molecule, which contains the heterologous gene
of interest to be expressed within the target cell or tissue. In a
preferred embodiment, the DNA vector molecule comprises
the gene of interest, which may be operatively linked to a
promoter, transcription enhancer and/or translation enhancer
to either produce high-level expression or cell specific
expression or both. Promoters, transcription and translation
enhancers for high-level and/or cell specific expression are
known to one of ordinary skill in the art. Preferably, the
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promoter is a white blood cell specific promoter. More prefmay be expanded to include eight to ten males and eight to ten
erably, the promoter is a red blood cell specific promoter.
females at each MOL Transfer of the CD45 .1 antigen from the
Most preferably, the promoter is ankyrin-1. Preferred enhancdonor mouse to recipient mice that contain the CD45.2 variers include the GATA-1 and HS-40 used in tandem together
ant of this antigen was measured. Both the CD45.1 and
with the ank:yrin-1 promoter.
CD45.2 variants are detected in blood by flow cytometry
Non-limiting examples of preferred viral vectors include
using fluorescein isothiocyanate (FITC) conjugated antibodadenovirus vector, adena-associated virus (AAV) vector, lenies and Phycoerythrin (PE) conjugated antibody from Pharmtivirus, murine leukemia virus or herpes-simplex virus (HSV)
ingen.
vector, or other viral vectors currently in development, and
Expression ofNeprilysin on Hematopoietic Cells.
preferably, replication deficient variants thereof. Preferably, 10
Blood is collected by retro orbital bleeding into heparinthe DNA viral vector is a lentivirus vector.
ized tubes, and diluted with PBS and dextran, the latter to
Non-limiting examples of preferred plasmid vectors
0.7% final concentration. The red blood cells and/or white
include pcDNA, pCMV or any other mammalian cells
blood
cells are collected after incubation at 3 7° C. and resusexpression plasmids containing the CMV promoter or other
15 pended in PBS for flow cytometry analysis for neprilysin
promoters.
using an FITC conjugated monoclonal antibody CLBTransplantation preferably occurs via injection of the
CALLA/1,4F9 from Research Diagnostics Inc. and for
transduced target cells into a mammalian host. The transneprilysin
activity measurements as noted below. The superduced target cells may be directly injected into the bone
natant is used to measure the percent ofCD45 .1 positive cells
marrow tissue of the mammalian host. Direct intra-bone marrow injection of bone marrow stem cells has been described 20 by flow cytometry. We have previously shown that dilution of
purified neprilysin into heparinized tubes does not affect its
by Kushida T, Inaba M, Hisha H et a!. Intra-bone marrow
enzymatic activity (data not included) thus validating the
injection of allogeneic bone marrow cells: a powerful new
ability to collect blood from animals and measure neprilysin
strategy for treatment of intractable autoimmune diseases in
activity without complications and artifacts from the collecMRL/lpr mice. Blood 2001; 97:3292-3299). Preferably transplantation is directed by intravenous injection of the trans- 25 tion method. It may be advantageous to lyse the red blood
duced target cells into the blood of the mammalian host. The
cells and isolate plasma membranes by centrifugation at 100,
OOOxg for 1 hr. The membrane fraction contains the neprilcells may enter bone and serves as a source of bone marrow
stem cells. Such and other techniques for transplantation of
ysin activity, which was confirmed in initial preliminary
the transduced target cells are known to one of ordinary skill
experiments.
30
in the art and are incorporated herein.
Measuring Neprilysin Activity.
In a preferred embodiment, a lentivirus-neprilysin (lentiviNeprilysin activity is measured with glutaryl-Ala-Alarus-NEP) construct is used to transduce hematopoietic stem
Phe-X where X=AMC (aminomethylcoumarin), MNA
cells derived from bone marrow, which transduced hemato(methoxynaphthylamine) or -pNA (para-nitroaniline) as a
specific synthetic substrate (Li C, Hersh LB. (1995) Neprilpoietic stem cells are then transplanted into a mammalian
host. Transplantation occurs by intravenous injection of the 35 ysin: assay methods, purification, and characterization.
infected stem cells into the circulatory system of the mamMethods Enzymol. 248:253-63.). Neprilysin cleaves glutaryl-Ala-Ala-Phe-X releasing glutaryl-Ala-Ala and Phe-X.
malian host. The transplanted neprilysin expressing stem
cells continuously express neprilysin on hematopoietic cells,
The reaction is stopped and the Phe-X is secondarily cleaved
e.g., white and red blood cells. The expressed neprilysin
to free Phe and either the highly fluorescent
degrades peripheral A~ and results in a lowering of brain A~ 40 AMC=aminomethylcoumarin or methoxynaphthylamine
through a "sink effect". Without intending to be limited by
groups or the visible para-nitroaniline by an added aminopeptidase, aminopeptidase M. The released aminomethylcoutheory, it is hypothesized that reduction of peripheral A~
marin or methoxynaphthylamine is quantitated fluorometricauses an imbalance in A~ levels in the periphery and the
CNS, resulting in A~ from the brain to be drawn out of the
cally while the released para-nitroaniline is quantitated
CNS into the periphery as A~ levels in the periphery decrease. 45 spectrophotometrically.
Transduction of Hematopoietic Stem Cells.
A modified one-step continuous assay using a recombinant
Transduction of hematopoietic stem cells is performed
aminopeptidase produced in the Hersh laboratory may be
used in place of the two-step assay (Li and Hersh, 1995). The
using bone marrow cells derived from a C57BL/6 donor
recombinant aminopeptidase is added directly to the assay in
mouse carrying the leukocyte common antigen variant
CD45.1. These cells are transduced with a lentivirus-NEP. 50 excess such that the reaction is monitored continuously.
The transduced bone marrow cells are subsequently transThompson, M. W. and Hersh L. B., Analysis of conserved
planted into a sublethally irradiated (600 rads for 3 min.)
residues of the human puromycin-sensitive aminopeptidase.
C57BL/6 recipient mouse that expresses the lenkocyte comPeptides. 2003 September; 24(9):1359-65; Ma Z, eta!. Promon antigen variant CD45.2. Optimization of neprilysin
teolytic cleavage ofthe puromycin-sensitive aminopeptidase
expression is carried out by varying the multiplicity of infec- 55 generates a substrate binding domain. Arch Biochem Biotion (MOl) from 10 to 100 to 1000. Twenty four (24) mice
phys. 2003 Jul. 1; 415(1):80-6; Thompson M W, Govinmay be used for these studies, 8 at each MOL For each 8 at
daswami M, Hersh LB. Mutation ofactive site residues ofthe
each MOl, the groups can be further subdivided into 4 males
puromycin-sensitive aminopeptidase: conversion of the
enzyme into a catalytically inactive binding protein. Arch
and 4 females to look for trends in expression based on sex
differences, as sex differences in the extent of amyloid depo- 60 Biochem Biophys. 2003 May 15; 413(2):236-42. The onesition have been reported in hAPP transgenic mice. (Callahan
step assay has been further modified for use in a 96 or 384 well
M J, et a!. (2001) Augmented senile plaque load in aged
fluorescence plate reader. This modified assay is about 10
female beta-amyloid precursor protein-transgenic mice. Am
times more sensitive than the discontinuous assay, it permits
linear initial rates to be measured, and it accommodates mulJ Pathol. 158: 1173-7; Lee JY, eta!. (2002)). Contribution by
synaptic zinc to the gender-disparate plaque formation in 65 tiple samples to be assayed at the same time. The neprilysin
inhibitors thiorphan and phosphoramidon are used to deterhuman Swedish mutant hAPP transgenic mice. Proc Nat!
mine the specificity of the reaction.
Acad Sci USA. 99:7705-10). If a trend is observed the study
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Once an optimal multiplicity of infection (MOl) is established, the time course for expression of neprilysin from one
to twelve months is determined by both fluorescence activated cell sorting (FACS) and determination of enzyme activity. Neprilysinlevels at 1, 2, 4, 6, 9, and 12months from blood
obtained through orbital bleeding is measured. This follows
since it has been shown that the peripheral administration of
A~ binding agents (gelsolin or ganglioside GM1) lowered A~
levels within a month (Matsuoka eta!., 2003).
Non-Tg C57BL/6 mice for optimizing expression of
neprilysin on bone marrow stem cells may be used and to
minimize the cost involved in producing or purchasing hAPP
Tg mice. C57BL/6NCr mice are obtained from the National
Cancer institute-Frederick, Animal Production Program, Frederick, Md.
Transplantation and Analyzing A~ Levels.
Once the expression of neprilysin has been optimized in
C57BL/6 mice the optimal parameters are used to express
neprilysin in the 120 or other hAPP transgenic mouse lines,
i.e. the 3x-Tg mouse ofOddo eta!. (Triple-transgenic model
ofAlzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 39:409-421
(2003) ). Bone marrow transplantation is performed into mice
two months of age and measure A~ levels every month out to
eighteen months. Plasma is obtained either through orbital
bleeding or tail bleeding into heparinized tubes without sacrificing the animals, or if necessary from trunk blood after
sacrifice. The method of obtaining blood and therefore the
number of animals required depends on the A~ levels and the
sensitivity of our assay. Plasma is obtained by centrifugation
at 1,000xg for 10 min and used for A~ determination. The
plasma A~ levels in 120 or other hAPP Tg mice receiving
bone marrow cells transduced with wild type neprilysin is
compared to 120 or other hAPP mice receiving lentivirus
expressing an E585V neprilysin mutant, which is an inactive
form of the enzyme.
The plasma A~ levels are determined by sandwich ELISA.
Commercial ELISA kits from Biosource International or
ELISA plates produced in the laboratory from commercially
available antisera can be used. These are mouse monoclonal
antibodies 6E1 0 and 4G8 to human amyloid beta protein, or a
rabbit polyclonal antibody to specific to A~ 40 or specific to
A~ 42 respectively, obtained from Signet, (Dedham, Mass.)
to measure total A~, as well as measuringA~ 40 andA~ 42 . To
determine the fraction of A~ present as oligomers, the plasma
sample is subjected to PAGE using Tricine gels commercially
available from Invitrogen and immunostained with monoclonal antibody 6E1 0 (Signet Pathology Systems, Inc.) or our
own polyclonal antisera made to A~ residues 21 to 30.
Analyzing Expression of Neprilysin on Hematopoietic
Cells on Brain A~ Levels and Amyloid Deposition in the
Brain ofhAPP Transgenic Mice
Having determined the time course and to what extent
plasma A~ levels can be decreased by expression of neprilysin on hematopoietic cells, the effect of this peripheral
neprilysin expression on brain A~ levels is tested. Forty eight
(48) two-month old hAPP transgenic mice (i.e., the 120
mouse or the "triple transgenic" mouse of Oddo S et a!.
triple-transgenic model ofAlzheimer's disease with plaques
and tangles: intracellular Abeta and synaptic dysfunction.
Neuron. 39:409-421 (2003)), half undergoing bone marrow
transplantation with stem cells expressing neprilysin and the
other half undergoing bone marrow transplantation with stem
cells expressing the inactive E585V mutant neprilysin are
used. Six mice in each group (active versus inactive neprilysin) are sacrificed at 3 month intervals for up to eighteen
months following maximal neprilysin expression. The brains

from these mice are collected and used to measure total brain
A~, A~ 1 _40 and A~ 1 _42 levels. For measuring A~ levels, the A~
peptides are extracted with formic acid according to the procedure of Refolo L M, et a!. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic
mouse model. Neurobiol. Dis. 7:321-31 (2000), or with
guanidine (Masliah E, et a!. beta-amyloid peptides enhance
alpha-synuclein accumulation and neuronal deficits in a
transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Nat! Acad Sci USA. 2001 Oct. 9;
98(21):12245-50) and then determined by sandwich ELISA
using kits available from Biosource International. To determine the fraction of A~ present as oligomers, the sample is
subjected to PAGE using Tricine gels (commercially available from Invitrogen) and immunostained with monoclonal
antibody 6E10 (Signet Pathology Systems, Inc.) or our own
polyclonal antisera made to A~ residues 21 to 30.
Another group of thirty experimental and thirty control
mice are treated in a similar manner as above except that A~
deposition in these animals is measured. In both the 120 hAPP
and the 3x-Tg mouse A~ amyloid deposition is observed at
about 6 to 9 months of age and increases thereafter. Therefore
bone marrow transplantation is performed at about 2-3
months of age and the mice are euthanized at 6, 9, 12, 15 and
18 months of age in groups of 6. The mice are perfused
transcardially with 4% paraformaldehyde, the brains
removed and fixed overnight at 4 o C. The fixed brains are
rinsed in PBS, dehydrated, and then embedded in paraffin and
sectioned. Histological staining with hematoxylin-eosin,
cresyl-violet or silver impregnation as described by Bruce et
a!. (1996) is performed. Bruce, A. 1. et a!. (1996) Altered
neuronal and microglial responses to excitotoxic and
ischemic brain injury in mice lacking TNF receptors. Nat.
Med. 2: 788-794. Amyloid deposits are detected in cryostat
sections by incubation overnight at 4 o C. with biotinylated
mouse monoclonal antibodies 4G8) from (Signet, Dedham,
Mass.), The Elite kit from Vector Laboratories is used to
detect binding of the primary antibody. Sections are counterstained with hematoxylin/eosin and examined with a Nikon
light microscope. A minimum often sections per mouse are
examined. The number of plaques are counted and the size of
the plaques in the hippocampus are measured.
Analyzing Effect of Expression ofNeprilysin on Hematopoietic Cells and the Number of Amyloid Plaques in Older
hAPP Tg Mice.
To demonstrate the hypothesis that lowering of brain A~
levels through peripheral expression of neprilysin in the
plasma of older hAPP Tg mice leads to a decrease in the
number of preformed amyloid deposits, the same basic protocol as set forth above is used except that the recipient hAPP
transgenic mice (i.e. 120 mice) are 18-20 months old, a time
in which amyloid deposits are numerous in this transgenic
line. Bone marrow stem cells are transduced at the optimal
viral MOl and then bone marrow transplantation is performed
into the older 120 mice as described herein. Plasma A~ levels
through analysis ofblood obtained through orbital or tail vein
bleeding. Once the plasma A~ levels have been decreased to
a steady-state level, the animals are sacrificed at various times
(1 to 3 months initially) to determine if clearance of plasma
A~ has reversed amyloid plaque deposition in the brain. In
our studies with direct expression of neprilysin in the brains
of older mice (Marr et a!, 2002), a decrease in the number of
amyloid plaques was observed within a month. Ten (10) mice
expressing wild type neprilysin on red blood cells are compared to ten (10) mice expressing the inactive mutant nepril-
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ysin on red blood cells at one month, three months, six
months, and then at 6 month intervals until 2 years of age if
feasible.
Transcardial perfusion with 4% paraformaldehyde is used
after which the brains are removed and fixed. The fixed brains
are rinsed in PBS, dehydrated, and then embedded in paraffin.
Histological staining is performed on the paraffin embedded
sections, with amyloid deposits detected with biotinylated
mouse monoclonal antibodies 3D6 and 1ODS as noted above.
Counterstained sections are quantitated with a Nikon light
microscope. At least ten sections per mouse are used where
the number, size, and appearance of plaques in the hippocampus determined. To ensure that the results obtained are not
unique to the particular HAPP mouse line, (i.e. the J20
mouse) hAPPswE_presenilin-1 mice commercially available
from Jackson labs or the triple transgenic mouse line will be
used as controls.
In Vivo Delivery of Amyloid Peptide Inactivating Enzyme.
In another embodiment the present invention involves
direct in vivo delivery of an amyloid peptide inhibiting
enzyme gene to the bone marrow tissue of a mmalian host
through use of either an adenovirus vector, adena-associated
virus (AAV) vector, lentivirus, or herpes-simplex virus
(HSV) vector, murine leukemia virus (MuLV) or other viral
vectors currently in development. In this embodiment, a DNA
sequence of interest encoding a functional amyloid peptide
inhibiting enzyme or enzyme fragment is subcloned into the
respective viral vector. The amyloid peptide inhibiting
enzyme gene containing viral vector is then grown to
adequate titer and introduced into the bone marrow, preferably by injection into blood. In an exemplary procedure, the
region from the inguen to the knee joint is shaved, and a 5-mm
incision is made on the thigh. The knee is flexed to about a 90°
angle, and the proximal side of the tibia is drawn to the
anterior. A 26-gauge needle is inserted into the joint surface of
the tibia through the patellar tendon and then inserted into the
BM cavity. Using a microsyringe (50 f.tl; Hamilton Co.; Reno,
Nev.). Bone marrow cells are injected from the bone holes
into the bone marrow cavities of both tibiae.
Direct bone marrow tissue injection of a DNA molecule
containing the gene of interest results in transfection of the
recipient bone marrow tissue cells and hence bypasses the
requirement of removal, in vitro culturing, transfection,
selection, as well as transplanting the DNA vector containing
hematopoietic stem cells to promote stable expression of the
heterologous gene of interest.
In another embodiment, and as an additional alternative to
the in vitro manipulation of hematopoietic stem cells, the
gene encoding the product of interest is introduced into the
area of bone marrow tissue as naked DNA. The naked DNA
enters the bone marrow tissue cells, preferably hematopoietic
stem cells, resulting in an in vivo gene expression of the
amyloid peptide inhibiting enzyme on hematopoietic cells.
Coupling Amyloid Peptide Inactivating Enzyme to
Hematopoietic Cells.
In another aspect the present invention provides methods
of reducing amyloid peptide in the brain comprising inactivating peripheral amyloid peptide by coupling amyloid peptide inactivating enzymes to hematopoietic cells. Without
intending to be bound by theory, by coupling one or more
amyloid peptide inactivating enzyme to one or more hematopoietic cell the amyloid peptide inactivating enzyme is not
degraded in vivo so rapidly. The longer the amyloid peptide
inactivating enzyme is in circulation increases the opportunity of the amyloid peptide inactivating enzyme coming into
contact with peripheral A~ and inactivating the peripheral A~.

The present invention discloses ex vivo and in vivo techniques for coupling amyloid peptide inactivating enzyme
with hematopoietic cells. Generally, the ex vivo techniques
involve taking a sample of hematopoietic cells, in vitro coupling of one or more amyloid peptide inactivating enzyme to
one or more hematopoietic cell, followed by transplantation
of the sample having amyloid peptide inactivating enzymebound hematopoietic cells to the mmalian host, so as to
effect increased presence and activity of peripheral amyloid
peptide inactivating enzyme. It will be understood by the
artisan of ordinary skill that the preferred source of hematopoietic cells for treating a human patient is the patient's own
hematopoietic cells, such as red and white blood cells.
There are many techniques known by the skilled artisan for
coupling one or more molecule or compound to another,
which may be used to practice the present invention. In one
preferred embodiment, coupling may be achieved by biotinylating one or more amyloid peptide inactivating enzyme
and one or more hematopoietic cell of a mmalian host, and
linking the biotin of one or more of each the enzyme and the
hematopoietic cell using streptavidin and/or avidin, in accordance with the protocol set forth and incorporated in its
entirety by reference herein (Dominici S, et a!. Red blood
cell-mediated delivery of recombinant HIV-1 Tat protein in
mice induces anti-Tat neutralizing antibodies and CTL. Vaccine. May 16; 21(17-18):2073-81 (2003)). Other cross-linking reagents may also be used to link the two molecules to
effect coupling of enzyme and hematopoietic cells. Nonlimiting examples of such other cross-linking reagents
include glutaraldehyde, (Perez M T et a!. In vivo studies on
mouse erythrocytes linked to transferrin. IUBMB Life. 2002
September; 54(3): 115-21 ).
In another preferred embodiment, coupling may be
achieved by modifYing one or more amyloid peptide inactivating enzyme such that the modified enzyme binds to one or
more hematopoietic cell. Preferably, one or more amyloid
peptide inactivating enzyme is modified to contain a C-terminal human red blood cell binding peptide sequence as
described in, and incorporated in its entirety by reference
herein, Garcia J E, et a!. Peptides from the Plasmodium falciparum STEVOR putative protein bind with high affinity to
normal human red blood cells. Peptides. 2005 July; 26(7):
1133-43; Lopez R, eta!. Plasmodiumfalciparum: red blood
cell binding studies of peptides derived from histidine-rich
KAHRP-I, HRP-II and HRP-III proteins. Acta Trap. 2000
May 31; 75(3):349-59. It is also preferable to modify one or
more amyloid peptide inactivating enzyme such that it is
coupled or bound to an antibody to a hematopoietic cell in
accordance with the methods described in, and incorporated
in its entirety by reference herein, Spitzer D, et a!., ScFvmediated in vivo targeting of DAF to erythrocytes inhibits
lysis by complement. Mol Immunol. 2004 February; 40(13):
911-9. An antibody to a hematopoietic cell may be an antibody to a red blood cell or a white blood cell, or a platelet or
capable of binding all three. Due to such modifications, the
modified enzymes are able to couple to one or more hematopoietic cell.
In another preferred embodiment, coupling may be
achieved by modifYing one or more amyloid peptide inactivating enzyme such that the modified enzyme contains a
glycoinositol phospholipid (GPI) that permits direct insertion
of the protein into the membrane of one or more hematopoietic cells. Preferably, one or more amyloid peptide inactivating enzyme is modified to contain a GPI anchor as described
in and incorporated herein by reference Howell S, Lanctot C,
Boileau G, and Crine P, Expression of an enzymically active
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glycosylphosphatidylinositol-anchored form of neutral
endopeptidase (EC 3.4.24.11) in Cos-1 cells, Biochem. J.
(1994) 299:171-176.
In vivo techniques for coupling one or more amyloid peptide inactivating enzyme to one or more hematopoietic cell of
a mammal involve, modifYing in vitro one or more amyloid
peptide inactivating enzyme such that it will bind to one or
more hematopoietic cell and introducing the modified amyloid peptide inactivating enzyme into a mammalian host,
preferably by injection into the blood or bone marrow. Amylaid peptide inactivating enzymes are modified as described
above or in any such other marmer so that the modified
enzyme is capable of coupling with or to one or more hematopoietic cell.
Pharmacological Agents to Induce Synthesis or Activity of
Amyloid Peptide Inactivating Enzyme.
In another aspect the present invention provides the use of
pharmacological agents to induce synthesis of the endogenous gene encoding peripheral amyloid peptide inhibiting
enzyme. Such a pharmacological substance may be a compound that "up regulates" or enhances the expression of
peripheral amyloid peptide inhibiting enzyme. The pharmacological agent may bind to the regulatory region of the gene
encoding the peripheral enzyme and thus activate its gene
expression. Thus, the compound may be a transcriptional
activator of the gene encoding the enzyme. Or, the compound
may have a regulatory effect post transcriptionally in, for
example, stabilizing the amyloid peptide inhibiting enzyme
structure.
In still another aspect, pharmacological agents can be used
to increase the activity of the peripheral amyloid peptide
inhibiting enzyme. Such a pharmacological substance may be
a compound that enhances the activity of the peripheral amyloid peptide inhibiting enzyme. The pharmacological agent
may modulate the activity of the amyloid peptide inactivating
enzyme, causing an increase in activity of the peripheral
amyloid peptide inhibiting enzyme. Amyloid peptide inactivating enzyme enhancing substances may be bound to either
one or both of amyloid peptide inactivating enzymes modified to couple with hematopoietic cells and hematopoietic
cells for enhanced peripheral amyloid peptide inactivating
activity.
The pharmacological agent may be placed in pharmaceutically acceptable excipient or carrier and administered to a
person or individual in need thereof. Depending on the specific clinical status of the disease, administration can be made
via any accepted systemic delivery system, for example, via
oral route or parenteral route such as intravenous, intramuscular, subcutaneous or percutaneous route, or vaginal, ocular
or nasal route, in solid, semi-solid or liquid dosage forms,
such as for example, tablets, suppositories, pills, capsules,
powders, solutions, suspensions, cream, gel, implant, patch,
pessary, aerosols, collyrium, emulsions or the like, preferably
in unit dosage forms suitable for easy administration of fixed
dosages. The pharmaceutical compositions include a conventional carrier or vehicle and the pharmacological compound
and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, and so on.
If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary
substances such as wetting or emulsifYing agents, pH buffering agents and the like, such as, by non-limiting example,
sodium acetate, sorbitan monolaurate, triethanolamine oleate, and so on.
The compounds of this invention are generally administered as a pharmaceutical composition comprising a pharmaceutical vehicle in combination with the pharmacological

compound. The amount of the drug in a formulation can vary
within the full range employed by those skilled in the art, e.g.,
fromaboutO.Ol weight percent (wt %) to about 99.99 wt% of
the drug based on the total formulation and about 0.01 wt%
to 99.99 wt% excipient.
The preferred mode of administration, for the conditions
mentioned above, is oral administration using a convenient
daily dosage regimen, which can be adjusted according to the
degree of the complaint. For said oral administration, a pharmaceutically acceptable, non-toxic composition is formed by
the incorporation of the selected pharmacological compound
in any of the currently used excipients, such as, for example,
pharmaceutical grades of marmitol, lactose, starch, magnesium stearate, sodium saccharine, talc, cellulose, glucose,
gelatin, sucrose, magnesium carbonate, and the like. Such
compositions take the form of solutions, suspensions, tablets,
pills, capsules, powders, sustained release formulations and
the like. Such compositions may contain between 0.01 wt%
and 99.99 wt% of the active compound according to this
invention.
Preferably the compositions have the form of a sugar
coated pill or tablet and thus contain, along with the active
ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, and the like; a disintegrant such as starch or derivatives
thereof; a lubricant such as magnesium stearate and the like;
and a binder such as starch, polyvinylpyriolidone, acacia
gum, gelatin, cellulose and derivatives thereof, and the like.
It is understood that by "pharmaceutical composition", it is
meant that the pharmacological compound is formulated into
a substance that is to be administered purposefully for modulating amyloid peptide inactivating enzymes to inactivate
peripheral amyloid protein. The mode of action is believed to
be by hydrolytic cleavage of the amyloid peptide by the
amyloid inactivating enzyme U.S. Published PatentApplication No. 2003/0165481 published on Sep. 3, 2004. However,
it is understood that the pharmacological compound per se
will not have a toxic effect, and by "pharmaceutical composition", it excludes those compositions that are used to administer to individuals as test compounds for a purpose other than
as an inducer of inactivation of the amyloid protein.
Treating and/or Preventing Alzheimer's Disease
It is another aspect of the present invention to treat and/or
prevent Alzheimer's Disease. In one embodiment, the method
comprises administering to a patient in need thereof a therapeutically effective amount of stem cells transduced with a
DNA vector encoding an amyloid peptide inactivation
enzyme as described herein. Preferably the stem cells are
hematopoietic stem cells including but not limited to red
blood cells, white blood cells, and platelets. Preferably the
DNA vector is a viral vector, and most preferably a lentivirus
vector or an adena associated virus vector. It is also preferable
that the amyloid peptide inactivating enzyme is a peptidase,
and most preferably, the peptidase is neprilysin or a biologically active derivative or fragment thereof. In another preferred embodiment, the method comprises administering (ex
vivo or in vivo) to the hematopoietic stem cells of a patient in
need thereof a therapeutically effective amount of a recombinant viral vector or plasmid vector comprising a nucleotide
sequence encoding an amyloid peptide inactivating enzyme
operatively linked to a promoter such that it is expressed on
the surface of or secreted from hematopoietic cells.
In another embodiment, the present invention provides a
method for treating and/or preventing Alzheimer's disease by
administering to the hematopoietic cells of a patient in need
thereof a thereapeutically effective amount of amyloid peptide inactivating enzyme. Preferably the enzyme is administered by coupling amyloid peptide inactivating enzyme to
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hematopoietic cells as described herein. Coupling may be
performed ex vivo and then the enzyme-coupled hematopoietic cells are transplanted in to a patient, or it may occur in
vivo via modified amyloid peptide inactivating enzymes.
Preferably, coupling is performed ex vivo via biotinylation of
amyloid peptide inactivating enzyme and hematopoietic cells
and using streptavidin and/or avidin to link one or more
biotiny Iated enzyme to one or more hematopoieteic cell. Coupiing is preferably performed in vivo by modifying amyloid
peptide inactivating enzyme and introducing the modified
enzyme into a patient. Preferably, amyloid peptide inactivating enzyme is modified to contain either a C-terminal human
red blood cell binding peptide sequence, or a glycoinositol
phospholipids (GPI) anchor. It is also preferable to bind an
antibody to a hematopoietic cell to an amyloid peptide inactivating enzyme to produce a chimeric protein in which the
antibody combining region is directed against a hematopoietic cell surface protein. Preferably the modified enzyme is
introduced by injection into the blood of a patient.
In another embodiment, there is a method for treating
and/or preventing Alzheimer's disease by administering to
the blood of a patient a therapeutically effective amount of an
amyloid peptide inactivating enzyme-containing liposome or
other delivery agent. Preferably, the amyloid peptide inactivating enzyme-containing liposomes introduce the enzyme
into hematopoietic cells of the patient. The amyloid peptide
inactivating enzyme-containing liposome may be delivered
ex-vivo into the hematopoietic cells of a patient and then
transplanted into a patient or delivered in vivo into the
hematopoietic cells of a patient.

globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells. Hum Gene Ther. 13:2007-2016, and MoreauGaudry F, et a!. (2001) High-level erythroid-specific gene
expression in primary human and murine hematopoietic cells
with self-inactivating lentiviral vectors. Blood 98:26642672. These are self-inactivating lentiviral vectors that use an
erythroid specific enhancer in combination with the woodchuck hepatitis virus post regulatory element and produce
erythroid specific expression in both murine and human cell
lines. In a preferred embodiment, the lentivirus constructs
contain ank:yrin-1 promoter in combination with two enhancers in tandem (the GATA-1 and HS-40). FIG. 8 (A-B) illustrates exemplary lentiviral constructs for the expression of
NEP on red blood cells.
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EXAMPLE 1
Lentivirus Constructs for Expression in
Hematopoietic Cells
Lentivirus constructs for expression in hematopoietic cells
were generated as described by Dull T, et a!. A third-generation lentivirus vector with a conditional packaging system. J
Viral. 1998 November; 72(11):8463-71.). Vector plasmids
were constructed for the production of third generation lentiviral vectors. All vectors were designed to be self-inactivating and used the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) 3' to the transgene. The
human cytomegalovirus (CMV) promoter was used to drive
expression of the transgenes. The HIV-1 central poly-purine
track were also located 5' to the promoter. Lentiviral vectors
were produced using a four plasmid transfection system, as
described by Dull eta!. 1998. Briefly, 293T cells were transfected with vector and packaging plasmids, the supernatants
are collected, and vectors are concentrated by centrifugation.
The lentiviral vector titers were estimated by measuring the
amount ofHIV p24 gag antigen with an ELISA kit (Zeptometrix Co., Buffalo, N.Y.). FIG. 1 illustrates an exemplary
lentiviral vector construct used for expression of NEP on
hematopoietic cells.
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Lentivirus constructs for expression in red blood cells were
generated in the laboratory of Dr. Punam Malik of UCLA
according to the methods described in and incorporated in
their entirety by reference herein to Hanawa H, eta!. (2002)
High-level erythroid lineage-directed gene expression using

To evaluate the use of neprilysin as a potential candidate for
a gene therapeutic approach for treating AD, the following
lentivirus constructs were tested, comprising: (1) the neprilysin gene (NEP), (2) an inactive point mutant of neprilysin
(NEPx), (3) a secreted form of neprilysin (SecNEP) that
produces the extracellular domain, and (4) green fluorescent
protein (GFP), each driven by the cytomegalovirus (CMV)
promoter. These constructs were initially tested in a Chinese
hamster ovary (CHO) cell line, 7PA2, (obtained from Dr.
Deunis Selkoe) that is stably transfected with hAPP and that
secretes relatively large amounts of A~ into the media. As
shown in FIG. 2, transduction of CHO 7PA2 cells with lentivirus expressing neprilysin or the secreted form of neprilysin produces a large decrease in the concentration of A~ 1 _42
and A~ 1 -4 0 in the media. In contrast, the inactive form of
neprilysin produced no significant effect. We further found
that transduction of the CHO 7PA2 cell line at a low multiplicity of infection, about 1 multiplicity of infection (MOl),
produced a similar effect to that shown in FIG. 2 indicating
that even low level expression of neprilysin is sufficient to
efficiently degrade extracellular A~. Dr. Selkoe's group has
recently measured the kinetics ofA~ hydrolysis by neprilysin
using anA~ analog (Leissring MA, eta!. (2003) Kinetics of
amyloid beta-protein degradation determined by novel fluorescence- andfluorescence polarization-based assays. J. Bioi
Chern. 278:37314-20) and found a Km of about 10 f.LM.
EXAMPLE4
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Bone marrow was harvested from 6-week-old C57BII
LY5.1 mice (B/6.SJL-CD45a-Pep3b, Jackson Laboratory,
Bar Harbor, Me.) (CD45.11) by flushing femurs and tibiae.
Lineage-negative cells were purified with the Hematopoietic
Progenitor Enrichment kit from Stemcell Technologies.
Enriched progenitor cells were prestimulated with Iscove's
modified Dulbecco's medium (IMDM; Gibco, Grand Island,
N.Y.) supplemented with 10% FCS containing 10 ng/mL of
each of the following cytokines: miL3, miL6, hF!t3 ligand
and 50 ng/ml hSCF (R&D, Minneapolis, Miun.) overnight
and then transduced with lentiviral vectors two times at
24-hour intervals. On day 3, cells were washed twice with
phosphate buffered saline (PBS) and 2x105 hematopoietic
cells/mouse were injected into the tail vein of 8-week-old
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rec1p1ent male PDAPP mice (transgenic C57BL/6-ly5.2
(CD45.21) mice that over express mutant human amyloid
precursor protein eDNA (hAPPV717F) under the control of
the platelet-derived growth factor promoter), which was sublethally irradiated to allow full engraftment of the transplanted hematopoietic stem cells (6 Gy).
As shown in FIG. 4, transplantation of bone marrow cells
from a donor mouse expressing the leukocyte common antigen variant CD45 .1 into a sublethally irradiated (600 Rads for
3 min) two month old CD45.2 positive recipient mouse generates a chimeric animal in which 30 days after transplantation approximately one third of the circulating hematopoietic
cells are derived from the donor as shown by the number of
CD45.1 positive cells. The generation of these chimeric mice
demonstrates the ability to isolate bone marrow stem cells and
to successfully perform bone marrow transplantation in mice.
FIG. 4A is a histogram of a recipient mouse's white blood
cells 30 days after bone marrow transplantation. FITC conjugated anti CD45.1 antibody A20 (PharMingen) was used.
Cells in the M1 region are CD45 .1 +donor cells and represent
about 30% of the total cells. FIG. 4B is a histogram of the
same recipient mouse's white blood cells as in the left panel,
but without FITC conjugated anti CD45 .1 antibody. There are
less than 0.1% cells appearing as CD45.1 positive cells. FIG.
4C is a histogram of a recipient mouse without bone marrow
transplantation. There are less than 0.1% cells appearing as
CD45.1 +cells.

ent mouse receiving inactive NEP-lentivirus transduced bone
marrow cells and shows greater than 20% of the white blood
cells express neprilysin.

EXAMPLES
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ELISA Quantitation of Brain A~ Peptides
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Neprilysin Expression on White Blood Cells
As shown in FIG. S, the NEP-lentivirus are used to transduce bone marrow stem cells from a donor mouse as
described in FIG. 4 which are transplanted into a two month
old recipient mouse producing neprilysin expression on white
blood cells. About 65% of the white blood cells expressed
neprilysin prior to transplantation, however since the white
blood cells represent -1% of total blood cells, a relatively
small amount ofNEP expression is obtained.
FIG. SA (left) is a histogram of a recipient mouse 30 days
after bone marrow transplantation. FITC conjugated antiNEP antibody CLB-CALLA/1,4F9 (RDI) was used. Cells in
the M2 region are neprilysin positive cells and represent
about 30% of the total cells. FIG. SA (middle) is a histogram
of a recipient mouse without bone marrow transplantation.
There are less than 0.1% cells appearing as neprilysin positive
cells. FIG. SA (right) is a histogram of a recipient mouse after
bone marrow transplantation without FITC conjugated anti
CLB-CALLA/1 ,4F9 antibody. There are less than 0.1% cells
appearing as CD45.1 positive cells.
FIG. SB is a repeat and extension of the experiment ofFIG.
SA. The NEP-lentivirus was used to transduce bone marrow
stem cells from a donor mouse, which were transplanted into
a two-month old recipient mouse producing neprilysin
expression on white blood cells. About 65% of the bone
marrow white blood cells used for transplantation expressed
neprilysin. Cells in the M1 region are neprilysin positive
cells. Control is a histogram of a recipient mouse without
bone marrow transplantation. There are less than 2% cells
appearing as neprilysin positive cells. The panel labeled NEP
is a histogram of cells from a recipient mouse receiving
NEP-lentivirus transduced bone marrow cells and shows
greater than 20% of the white blood cells express neprilysin.
The panel labeled NEPx is a histogram of cells from a recipi-

EXAMPLE 6
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One (1) year after bone marrow transplantation as set forth
in Example 4, animals were sacrificed and peripheral blood
and brain were harvested. In blood, red blood cells (RBCs,
erythrocytes) were analyzed before RBC lysis for white
blood cell (WBC, lymphocytes) analyses. FACS analysis was
performed for donor cells (CD45.2), NEP expression in different lineages (T cells, B cells, granulocytes, and RBCs ), and
DNA analysis to determine proviral copy number.
Brains were removed immediately after euthanasia of the
mice by C0 2 narcosis, frozen in liquid nitrogen, and stored
frozen until extraction. Brains were homogenized in 5M
guanidine.HCl in 50 mM Tris.HCI. After incubation for 4 hat
room temperature, the homogenate was diluted with cold
BSAT-DPBS buffer (5% BSA, 0.03% Tween-20 in DPBS)
and centrifuged at 16,000xg for 20 min at 4° C. to remove
insoluble material. Supernatant fractions were analyzed for
A~ 40 andA~ 42 using isoform-specific ELISA kits (Biosource
International, Camarillo, Calif.). As set out in FIG. 6, mice
with bone marrow transplantation of white blood cells
expressing active NEP showed reduction of A~ levels in the
brain over mice with bone marrow transplantation of white
blood cells expressing inactive NEP. Mice with bone marrow
transplantation of white blood cells expressing active NEP
showed about a 47.5% reduction inA~ 1 -4 0 levels in the brain.
Mice with bone marrow transplantation of white blood cells
expressing active NEP showed about a 30% reduction in
A~ 1 _42 levels in the brain.
EXAMPLE 7
Biotinylation ofNeprilysin
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Purified neprilysin (1.8 flg) was treated with 2.5 flg of
N-hydroxysuccinimde-biotin in a 100 fll reaction containing
100 mM HEPES buffer, pH 8, for the indicated times. An
aliquot oflO fll (0.18 mg) was withdrawn and then subjected
to SDS-PAGE, transferred to a PVDF membrane, and then
treated with 1/2000 of avidin HRP, and visualized by
enhanced chemiluminescense (ECL). Samples at 0, 1 and 2
hrs contained 10 fll ofthereactionmixture, while the 4 and 18
hr samples contained 5 fll.
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EXAMPLE 8
Biotinylated Neprilysin Retains Activity
55
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Purified neprilysin treated with 2.5 mg ofN-hydroxysuccinimde-biotin for the indicated time as in example 7 was
assayed for neprilysin activity using glutaryl-Ala-Ala-PheMNA (MNA=methoxynaphthylamide) as substrate. As
shown in FIG. 10 about 75% of the activity relative to the
untreated control was retained after 2 hrs.
EXAMPLE 9
Biotinylation oflsolated Red Blood Cells
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A 10% red blood cell suspension was treated with 75 f.LM
N-hydroxysuccinimde-biotin at room temperature for 2 h in
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phosphate buffered saline (PBS). After incubation, the red
blood cell suspension was washed with PBS containing BSA
at 2 mg/ml. FITC-streptavidin was used for FACS analysis.
As shown in FIG. 11, Panel A is a control of untreated red
blood cells. Panel B shows more than 75% of the red blood
cells contained biotin.

EXAMPLE 14
Neprilysin Modified to be Bound to an Antibody
5

EXAMPLE 12
Coupling ofBiotinylated Neprilysin to Red Blood
Cells
Twenty flg of biotinylated neprilysin (b-NEP) was incubated with 5 fll of packed streptavidin-conjugated biotinylated-red blood cells in 100 fll of PBS containing BSA at 2
mg/ml at room temperature for 1 hr. After washing 5 times,
the red blood cells were incubated with anti-neprilysinmonoclonal antibody labeled with FITC conjugated anti-neprilysin
antibody CD 1OF) at room temperature for half an hour. The
sample was then analyzed by FACS. Results in FIG. 12 show
that biotinylated neprilysin can be linked to biotinylated red
blood cells using streptavidin.

10

15

20

EXAMPLE 13
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Modified Neprilysin
Neprilysin was modified with a C-terminal human red
blood cell binding peptide sequence linked to the C-terminus
of the enzyme. See FIG. 13. The red blood cell binding
peptide is derived from a peptide sequence of the histidine
rich protein from P. falciparum according to the methods
provided and incorporated in their entirety by reference
herein to Lopez R, Urquiza M, Curtidor H, Eduardo Caminos
J, Mora H, Puentes A, Patarroyo M E. Plasmodium falciparum: red blood cell binding studies of peptides derived
from histidine-rich KAHRP-1, HRP-II and HRP-III proteins.
Acta Trap. 2000 May 31; 75(3):349-59.
FIG. 14 shows that modified neprilysin containing a C-terminal human red blood cell binding peptide sequence as
shown in example 13 is bound to human red blood cells. The
construct shown in FIG. 13 was transiently expressed in HEK
cells using a pCSC vector. A cell extract containing the modified NEP was prepared in PBS and incubated with human red
blood cells isolated from 1 ml of human blood in 0.2 ml of
PBS for 2 hrs at room temperature The sample was then
centrifuged and the NEP activity in the supernatant determined withglutaryl-ala-ala-Phe-MNAas substrate. Although
none of the uumodified NEP is depleted from the sample by
red blood cells, -50% of the modified NEP is removed by
binding to red blood cells.

FIG. 15. shows a schematic of neprilysin modified with a
single chain antibody directed against a red blood cell epitope
sequence linked to the C-terminus of the enzyme according to
the methods provided and incorporated in their entirety by
reference herein to Spitzer D, et a!., ScFv-mediated in vivo
targetingofDAF to erythrocytes inhibits lysis by complement.
Mol Immunol. 2004 February; 40(13):911-9. This chimeric
protein was shown to bind to mouse red blood cells.
Although illustrative embodiments of the present invention
have been described in detail, it is to be understood that the
present invention is not limited to those precise embodiments,
and that various changes and modifications can be effected
therein by one skilled in the art without departing from the
scope and spirit of the invention as defined by the appended
claims.
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What is claimed is:
1. A method for reducing amyloid peptide in the brain of a
patient in need thereof, said method comprising:
(a) generating a non-replicating recombinant viral vector
comprising a nucleotide sequence encoding neprilysin
operably linked to a promoter;
(b) obtaining hematopoietic stem cells from the patient;
(c) introducing the non-replicating recombinant viral vector into the hematopoietic stem cells ex vivo· and
(d) introducing the hematopoietic stem ~ells of s;ep (c) into
the patient via bone marrow transplantation or via intravenous injection, wherein the neprilysin is expressed in
the peripheral blood on the surface of one or more of the
hematopoietic cells at a sufficient level and duration to
result in the efflux of A~ protein from the brain and
facilitate degradation and clearance of A~ protein from
the peripheral blood.
2. The method according to claim 1 wherein the nonreplicating recombinant vector is a viral vector selected from
the group consisting of adena-associated virus (AAV) vector,
lentivirus, murine leukemia virus and herpes-simplex virus
(HSV) vector.
3. The method according to claim 1 wherein the hematopoietic cells are red blood cells, white blood cells, platelets or
a combination of all.
4. The method according to claim 3 wherein the hematopoietic cells are red blood cells.
5. The method according to claim 1, wherein said A~
protein is A~ 1 _40 or A~ 1 _ 42 .
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